

1 **Dynamics of the blood plasma proteome during hyperacute HIV-1 infection**

2 Jamirah Nazziwa^{1,2}, Eva Freyhult³, Mun-Gwan Hong⁴, Emil Johansson^{1,2}, Filip Årman⁵,
3 Jonathan Hare^{6,7}, Kamini Gounder^{8,9}, Melinda Rezeli⁵, Tirthankar Mohanty¹⁰, Sven
4 Kjellström⁵, Anatoli Kamali⁷, Etienne Karita¹¹, William Kilembe¹¹, Matt A Price^{7,12},
5 Pontiano Kaleebu¹³, Susan Allen^{11,14}, Eric Hunter^{11,14}, Thumbi Ndung'u^{8,9,15,16}, Jill Gilmour⁶,
6 Sarah L. Rowland-Jones¹⁷, Eduard Sanders^{17,18,19}, Amin S. Hassan^{1,18*}, and Joakim
7 Esbjörnsson^{1,2,17§*}

8

9 ¹Department of Translational Medicine, Lund University, Sweden

10 ²Lund University Virus Centre, Lund University, Sweden

11 ³Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden,
12 Science for Life Laboratory, Uppsala University, Uppsala, Sweden

13 ⁴National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of
14 Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden

15 ⁵BioMS–Swedish National Infrastructure for Biological Mass Spectrometry, Lund
16 University, Lund, Sweden

17 ⁶IAVI Human Immunology Laboratory, Imperial College, London, United Kingdom

18 ⁷IAVI, New York, New York, USA, and Nairobi, Kenya

19 ⁸Africa Health Research Institute, Durban, South Africa

20 ⁹HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of
21 KwaZulu-Natal, Durban, South Africa

22 ¹⁰Division of Infection Medicine, Department of Clinical Sciences Lund, Faculty of
23 Medicine, Lund University, Lund, Sweden

24 ¹¹Rwanda/Zambia HIV Research Group, Kigali, Rwanda, and Lusaka, Zambia

25 ¹²UCSF Department of Epidemiology and Biostatistics, San Francisco, California, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 1 ¹³Medical Research Council/Uganda Virus Research Institute, Uganda, and London School of
- 2 Hygiene and Tropical Medicine, London, United Kingdom
- 3 ¹⁴Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
- 4 ¹⁵Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology
- 5 and Harvard University, Cambridge, Massachusetts, USA
- 6 ¹⁶Division of Infection and Immunity, University College London, London, United Kingdom
- 7 ¹⁷Nuffield Department of Clinical Medicine, University of Oxford, UK
- 8 ¹⁸KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
- 9 ¹⁹The Aurum Institute, Johannesburg, South Africa
- 10
- 11 *Authors with equal contribution
- 12 §Correspondence: joakim.esbjornsson@med.lu.se

1 **ABSTRACT**

2 HIV-1 remains incurable and there is no effective vaccine towards the infection. A main
3 challenge for this is the lack of a holistic understanding of the myriad of complex virus-host
4 interactions during hyperacute HIV-1 infection (hAHI), and how these contribute to tissue
5 damage and pathogenesis. Here, 1293 blood plasma proteins were quantified from 157 linked
6 plasma samples collected before, during, and after hAHI of 54 volunteers from four sub-
7 Saharan African countries. Six distinct longitudinal expression profiles were identified, of
8 which four demonstrated a consistent decrease in protein levels following HIV-1 infection.
9 Differentially expressed proteins were involved in inflammation, innate immunity, cell
10 motility, and actin cytoskeleton reorganisation. Specifically, decreased levels of Zyxin,
11 Secretoglobulin family 1A member 1, and Pro-platelet basic protein were associated with acute
12 retroviral syndrome; Rho GTPase activating protein 18, Annexin A1, and Lipopolysaccharide
13 binding protein with viral load; and Hepsin, Protein kinase C beta, and Integrin subunit beta 3
14 with disease progression. This is the first holistic characterisation of within-patient blood
15 plasma proteome dynamics during the first weeks of HIV-1 infection and presents multiple
16 potential blood biomarkers and targets for prophylactic and therapeutic HIV-1 interventions.

1 INTRODUCTION

2 While the blood plasma proteome typically remains stable in healthy individuals,
3 perturbations have been documented in response to different infections, including severe
4 acute respiratory syndrome coronavirus 2, and bacterial and viral pneumonia^{1,2}.
5 Understanding differential expression of plasma proteomics in these infections played a
6 pivotal role in informing diagnostic, prophylactic, and therapeutic interventions^{3,4}. In HIV-1
7 infection, virus-host interactions during the earliest stages of infection – the hyperacute HIV-
8 1 infection (hAHI, defined as the period from onset of plasma viremia to peak viral load) –
9 triggers a complex network of cell and tissue signalling that manifests as rapid systemic
10 immune activation and reorganisation of cellular microenvironments⁵⁻⁸. A part of this has
11 been associated with a cytokine storm, and some infected individuals show symptoms of
12 acute retroviral syndrome (ARS)⁹⁻¹². These events contribute to a significant loss of CD4+ T-
13 cells and germinal centres and play a critical role in shaping HIV-1 disease pathogenesis^{6,8,13-}
14 ¹⁵. Indeed, disease progression to AIDS in HIV-1 infected individuals varies widely, ranging
15 from a few months to several decades, and events during hAHI have been suggested to
16 strongly influence the rate of disease progression¹⁶⁻¹⁸. In blood, HIV-1 viraemia is detectable
17 approximately a week after infection, reaching a peak viral load (VL) of millions of virus
18 particles per ml 3-4 weeks after infection^{5,6}. During this period, a reservoir of latently
19 infected cells is also established, which remains one the main obstacles of curing HIV-1¹⁹.
20 After the peak VL, the viraemia gradually decreases and plateaus at a set-point level ~30-65
21 days after infection^{5,6}.

22

23 While pro-inflammatory and antiviral cytokines and chemokines have been studied
24 extensively, longitudinal studies investigating blood plasma proteins during hAHI are
25 lacking^{13,20,21}. Recent advancements in data-independent acquisition mass spectrometry

1 (DIA-MS) based proteomics has enabled simultaneous identification and quantification of
2 thousands of proteins in plasma across a large dynamic range, significantly expanding the
3 potential of detectable biomarkers²². Furthermore, the cellular and tissue expression patterns
4 of these proteins have been mapped in a human protein atlas, facilitating analysis of proteome
5 dynamics in response to infections²³. In this study, data and samples collected from two well-
6 characterised HIV-1 incidence cohorts from four sub-Saharan African countries were analysed
7 to elucidate dynamics of blood plasma proteome before, during and after hAHI, and to
8 determine associations with ARS, viral load responses, and HIV-1 disease progression.

1 RESULTS

2 Study participants

3 Overall, 54 participants from the East African (International AIDS Vaccine Initiative, IAVI,
4 cohort, n=39), and South African (Females Rising through Education, Support, and Health,
5 FRESH, and HIV Pathogenesis Programme, HPP, cohorts, Durban, n=15) met the eligibility
6 criteria, and were included in the analyses (Fig. 1)²⁴⁻²⁷. Participants contributed 157
7 longitudinally linked plasma samples from three time points including Visit 0 (V0), collected
8 at a median of 62 days prior to HIV-1 infection (interquartile range [IQR] 28-106 days); V1,
9 median 10 days after HIV-1 infection (IQR 10-14); and V2, median 31 days after HIV-1
10 infection (IQR 28-37)²⁸. Most participants were male (n=34, 63%), aged below 25 years
11 (n=32, 59%), from Kenya (n=32, 59%), infected with HIV-1 sub-subtype A1 (n=31, 57%),
12 and identified as men who have sex with men (MSM, n=28, 52%, Extended Data Table 1).

13

14 Human plasma proteome dynamics during hyperacute HIV-1 infection

15 To increase the number of detected proteins, each sample was analysed both neat and after
16 depletion of the 14 most abundant proteins (Fig. 1, Supplementary Information)²⁹. In total,
17 1549 protein profiles were detected, whereof 213 were excluded because they were missing
18 from more than 80% of the samples (Extended Data Fig. 1). Among the remaining 1336
19 proteins, 379 were collected from neat, and 957 from depleted plasma sample types. Of these,
20 1028 proteins had unique UniProt IDs and canonical protein form, of which 427 proteins had
21 previously been classified as secreted proteins, actively released into blood plasma, and 601
22 proteins as intracellular or tissue leakage proteins originating from tissues or dying cells^{30,31}.
23 To determine the longitudinal within-host dynamics across V0, V1, and V2 for each of the
24 1336 identified plasma proteins, kmeans and hierarchical clustering were used. The analysis
25 suggested six different longitudinal expression profiles (Fig. 2a). Of these, two demonstrated

1 a significant decline during hAHI with a rebound to pre-infection levels after hAHI (referred
2 to as “Rapid decrease-rapid increase”, and “Slight decrease-rapid increase”); two
3 demonstrated a decreased levels during and after hAHI (“Gradual decrease”, and “Rapid
4 decrease-slight increase”); one demonstrated an increase during hAHI followed with a
5 decline to pre-infection levels after hAHI (“Rapid increase-rapid decrease”); and one
6 demonstrated a sustained increase during and after hAHI (“Persistent increase”). The general
7 population-based protein dynamics based on mean protein intensities were also determined,
8 indicating that 616 (64%) of the depleted proteins decreased at V1, and that these proteins
9 were mainly involved in cell structure, motility, and transport (Extended Data Fig. 2).

10

11 Next, the proteins that were significantly differentially expressed between the study visits at
12 the individual level were determined. Explorative principal component analysis indicated
13 differential protein expression by cohort and visit, with South African participants clustering
14 separately from East African participants (Extended Data Fig. 3). When adjusting for this
15 potential confounder, 160, 240 and 226 proteins were significantly differentially expressed
16 between visits V1-V0, V2-V0 and V2-V1, respectively (Fig. 2b). Of these, two (V1-V0), 12
17 (V2-V0), and six (V2-V1) proteins were particularly altered between visits as defined by a
18 log₂ fold change (Log₂FC) >1 (Fig. 2c; Extended Data Table 2). Of the 160 differentially
19 expressed proteins at V1-V0, 82 proteins were upregulated, of which 57 were
20 overrepresented in gene ontology biological process (GO-BP) terms, including innate
21 immune responses, stress responses, antigen processing or presentation, and regulation of
22 vesicle-mediated transport (Fig. 2d). Of the 78 downregulated proteins, 28 were associated
23 with GO-BP terms such as negative regulation of hydrolase/peptidase activity and cellular
24 metabolic processes (Fig. 2e). Moreover, based on a previous tissue-specific transcriptional
25 signature dataset, significant tissue damage signatures associated with whole blood,

1 oesophagus mucosa and heart were observed in V1 compared to V0 (Extended Data Fig. 4)³².
2 When V2 was compared with V0, 111 proteins were upregulated, whereof 40 were linked
3 with different GO-BP terms involved in coagulation cascade/platelet activation, antigen
4 presentation, positive regulation of cell adhesion, and cardiac muscle cell differentiation (Fig.
5 2d). Of the 129 downregulated proteins, 82 were associated with GO-BP terms and related to
6 hydrolase/peptidase activity, and cellular metabolic processes. Finally, 206 of the 226
7 proteins that showed differential expression between V1 and V2 could be associated with
8 GO-BP terms, whereof 94 were upregulated. However, none of those were overrepresented in
9 any GO-BP term. In contrast, 67 of the 112 downregulated proteins with GO-BP terms were
10 overrepresented and could be related to immune response, response to external biotic
11 stimulus, complement activation, and regulation of peptidase activity (Fig. 2e). Further
12 analysis indicated that upregulated V2-V1 proteins were associated with tissue damage
13 signatures in adipose, cervical, muscle skeletal and lungs, whereas the downregulated
14 proteins were associated with tissue damage in skin and whole blood tissue (Extended Data
15 Fig. 4). Overall, these findings indicate that HIV-1 infection not only affects inflammatory or
16 immune markers, but also alters protein expression related to different metabolic processes,
17 cell mobility, and apoptosis.

18

19 **Decreased levels of Zyxin, Secretoglobin family 1A member 1, and Pro-platelet basic** 20 **protein during hyperacute HIV-1 infection is associated with ARS**

21 Data on AHI symptoms in the South African cohort were missing. Hence, associations
22 between protein dynamics and ARS were only conducted for participants from the East
23 African cohort (n=33, Fig. 3a). ARS was determined by latent class analysis based on the 11
24 symptoms including fever, headache, myalgia, fatigue, anorexia, pharyngitis, diarrhoea, night
25 sweats, skin rash, lymphadenopathy, and oral ulcers, as previously described⁹. The analysis

1 suggested that 20 of the 33 participants (61%) had ARS. Participants with ARS had
2 significantly higher prevalence in nine of the eleven symptoms than those without ARS
3 ($p < 0.05$; Fisher exact test, Fig. 3b). Next, Partial Least-Squares Discriminant Analysis (PLS-
4 DA) was used to identify proteins associated with ARS. This analysis demonstrated an
5 average accuracy of 78% (assessed through cross-validation) in predicting ARS in V1-V0
6 and V2-V0 differences (Fig. 3c). The PLS-DA analysis suggested that 20 differentially
7 expressed proteins with variance importance score above 2 could be potential indicators of
8 ARS (Fig. 3d-e). Notably, approximately half of these proteins at V1-V0 have been shown to
9 be actively secreted into plasma, and are primarily involved in regulation of inflammatory
10 responses, immunity, and host-virus interactions. Proteins identified at V2-V0 were annotated
11 as tissue leakage proteins and are primarily involved in cell motility and signalling (Extended
12 Data Table 3). Next, to confirm the association between the identified proteins and ARS, a
13 linear regression model with age as covariate was applied. The model showed that five of the
14 seven V1-V0 proteins that were determined as potential indicators of ARS in the PLS-DA
15 analysis were significantly associated with ARS (Fig. 3e-f). The linear regression model also
16 indicated that HRG was associated with ARS at V1-V0 (Fig. 3f). A hierarchical clustering
17 analysis of the proteins identified in the PLS-DA and linear regression model analyses was
18 used to identify the top proteins that distinguished participants with and without ARS (Fig.
19 3g). The analysis indicated clear differential expression of Secretoglobin family 1A member
20 1 (SCGB1A1), Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A),
21 Zyxin (ZYG), and Pro-platelet basic protein (PPBP) between these two groups (Fig. 3g-h).
22 More specifically, significant increases in ZYG, SCGB1A1, and PPBP at V1-V0 were
23 associated with the absence of ARS ($\text{Log}_2\text{FC} > \pm 1.5$, $p < 0.005$, Fig. 3h). Moreover, the
24 longitudinal expression profiles of these proteins indicated that >70% of individuals with
25 ARS had reduced levels of ZYG, SCGB1, and PPBP at V1-V0 (clusters 1-4, Fig. 3i). ZYG is

1 a cytoskeleton protein that has been shown to be a modulator of inflammatory response in
2 endothelial cells while SCGB1A1 is a pulmonary surfactant anti-inflammatory protein that
3 mediates inflammation and inflammation in the lungs following respiratory distress^{33,34}.
4 PPBP, also known as neutrophil-activating peptide-2 or CXCL7, is a cytokine produced by
5 platelets when bound to neutrophil cathepsin G in sites where aggregation of neutrophils and
6 platelets occur³⁵. Furthermore, according to the HIV-1 interactome databases, ZYX and three
7 other proteins have interactions with various HIV-1 proteins that can either enhance or inhibit
8 HIV-1 replication (Supplementary doc 1)³⁶. Collectively, these findings highlight a
9 connection between the magnitude of inflammation, innate immunity, and cell motility with
10 the manifestation of ARS.

11

12 **Rho GTPase activating protein 18, Annexin A1, and Lipopolysaccharide binding** 13 **protein are associated with HIV-1 control**

14 The period during which the VL was monitored varied between study participants. The
15 median follow-up time was four years after the estimated date of infection (EDI). To identify
16 plasma proteins associated with HIV-1 control, 9 study participants who either initiated
17 antiretroviral treatment (ART) within the first year of infection or were followed for less than
18 one year were excluded from the analysis (Fig 4a). The remaining 45 study participants
19 typically showed high levels of viremia following HIV-1 infection, which then subsequently
20 decreased and reached a viral load setpoint after approximately 50 days post the estimated
21 date of infection (EDI, Fig. 4b). The median peak VL was 6.0 (IQR 5.2-6.4) log₁₀ copies/ml
22 at a median of 19 (IQR 15-31) days post EDI, and the median nadir VL was 4.5 log₁₀
23 copies/ml at a median of 64 (IQR 43-73) days post EDI. Hierarchical clustering was used to
24 group the 45 study participants into two clusters based on their VL profiles during the first
25 year of infection (Fig. 4c). The clusters were defined as viral controllers (VL generally below

1 10,000 copies/ml for 12 months without ART, n=15), and non-controllers (VL generally
2 above 10,000 copies/ml for 12 months without ART, n=30, Fig. 4d). No clinical parameters,
3 or ARS were associated with viral control (Fig. 4e, Table S2).

4
5 Next, linear mixed models (with age and cohort as co-variables) was used to determine the
6 differentially expressed proteins that were associated with viral control. Four, seven and 18
7 proteins differed significantly between non-viral controllers (cluster 1) and sustained viral
8 controllers (cluster 2) at V1-V0, V2-V0, and V2-V1, respectively ($p < 0.005$; Fig. 4f). The
9 proteins represented acute phase and transport proteins with roles in innate immunity,
10 particularly in the regulation of inflammatory responses and cytokine release (Extended Data
11 Table 4). Specifically, compared with pre-infection levels, Rho GTPase activating protein 18
12 (ARHGAP18) was significantly higher among viral controllers at V1, whereas Annexin A1
13 (ANXA1), Lipopolysaccharide binding protein (LBP), and Pregnancy specific beta-1-
14 glycoprotein 1 (PSG1) levels were lower among viral controllers at V2 when compared to the
15 non-viral controllers ($\text{Log}_2\text{FC} > 2$, Fig. 4f). ARHGAP18 activates Rho GTPase, a regulator of
16 cell movement via actin cytoskeleton. Increased levels of ARGHAP18 have been previously
17 coupled to suppression of Rho GTPase thus affecting actin dependent binding of gp120 to the
18 CD4³⁷. Annexin is a pro-resolving and anti-inflammatory protein released into blood to
19 neutralise excess protease released by neutrophils following infection³⁸. Production of LBP is
20 induced by production of LPS and is a marker of microbial translocation. Increased levels of
21 LBP have been associated to increased activation which could explain why LBP levels are
22 lower among viral controllers³⁹. Interestingly, 14 of the proteins associated with viral control
23 have been found to interact with HIV-1 proteins in previous studies, primarily in enhancing
24 virus trafficking to the plasma membrane and infectivity enhancement (supplementary Doc
25 2)³⁶. Collectively, these results indicate a strong relationship between viraemia and cell

1 motility/transport (decreased among those with high viraemia) or innate immunity
2 inflammation (increased among those with high viraemia).

3

4 **Hepsin, Protein kinase C beta, and Glutathione S-transferase mu 2 are associated with**
5 **increased risk of disease progression**

6 Disease progression was defined using CD4⁺ T-cell responses. Participants contributed a
7 median of 13 (IQR: 10-18) CD4⁺ T-cell count observations during the 12 months of follow-
8 up after EDI (median CD4⁺ T-cell count 520, IQR: 404-657 cells/mm³). Fast progressors
9 were defined as individuals that reached a CD4⁺ T-cell count <500 cells/mm³ within 12
10 months from EDI (excluding measurements within the first six weeks), whereas slow
11 progressors were defined as individuals who maintained CD4⁺ T-cell counts >500 during the
12 same period. Among the 54 participants, 12 (22%) were classified as slow progressors, and
13 42 (78%) as fast progressors (Extended Data Fig. 5a). Study participants from South Africa
14 had a higher likelihood of slower disease progression compared with East African study
15 participants (p=0.08, Log-rank test, Extended Data Fig. 5b). In a Cox regression model,
16 controlling for age, sex, cohort, and subtype; seven, six, and 14 proteins were associated with
17 faster HIV-1 disease progression at V1-V0, V2-V0, and V2-V1, respectively (p<0.005, Fig.
18 5c, Extended Data Table 5). Specifically, increased levels of PRKCB (hazard ratio (HR) 1.3,
19 CI=1.1-1.6), HPN (HR=1.4, CI=1.1-1.7), CRHBP (HR=1.2, CI=1.1-1.3), PSMB6 (HR=1.3,
20 CI=1.1-1.5), TXNDC5 (HR=1.2, CI=1.1-1.4), and APOC4 (HR=1.3, CI=1.0-1.2) at V1-V0
21 were associated with an increased risk of HIV-1 disease progression. Decreased levels of
22 GSTM2 at V1-V0 was associated with a faster disease progression (HR=0.9, CI=0.8-1.0).
23 Interestingly, all these proteins have been shown to interact with the HIV-1 envelope
24 according to the HIV-1 interaction database (supplementary Doc 3)³⁶. Moreover, increased
25 levels of ITGB3 (HR=1.3, CI=1.1-1.5), HSPA8 (HR=1.1, CI=1.0-1.2), DDTL (HR=1.2,

1 CI=1.1-1.4) and UBB (HR=1.1, CI=1.0-1.2) at V2-V0 were associated with an increased risk
2 of disease progression. Decreased levels of CD84 (HR=0.9, CI=0.8-0.9) and LTBP1(HR=0.7,
3 CI=0.6-0.9) was associated with decreased risk of disease progression. Notably, all these
4 proteins have been shown to interact with different HIV-1 proteins to mediate cytokine
5 degradation (supplementary Doc 3).

6

7 **Longitudinal dynamics of key proteins during hyperacute HIV-1 infection**

8 Finally, a sliding window approach was used to generate spline curves reflecting the
9 population-based average dynamics of identified key proteins in blood plasma during hAHI
10 (Fig. 6). The protein levels were plotted relative to pre-infection levels for each study
11 participants at the day of sample collection post EDI. Key proteins associated with ARS, viral
12 control, and disease progression were selected based on the above analyses. For clarity,
13 proteins with similar dynamics in the group comparisons were excluded from this analysis.
14 The analysis showed an exceptional variability in the trajectory of the different proteins over
15 time and indicated that both the dynamics of overexpressed proteins (defined as *stormers*)
16 and underexpressed proteins (defined as *slumpers*) were common during hAHI.

1 DISCUSSION

2 Our study represents the largest and most comprehensive longitudinal MS-based study of
3 hAHI. In addition, determination of pre-infection protein levels for each study participant
4 enabled a unique assessment of the protein dynamics relative to HIV-1 uninfected levels at
5 the individual level. The analyses showed significant alterations of the plasma proteome
6 during hAHI, and most changes were transient as the infection progressed. Specifically,
7 elevated expression of SCGB1A1, ZYX, and PPBP during hAHI were associated with
8 absence of ARS; increased levels of ARHGAP18 during hAHI, and decreased levels of
9 ANXA1 and LBP after hAHI were associated with lower viremia; and increased levels of
10 HPN and PRKCB during hAHI, and ITGB3 and DDTL after hAHI, were associated with
11 faster disease progression. These findings are particularly interesting since they represent host
12 factors altered during hAHI that have not been linked to ARS and HIV-1 pathogenesis
13 previously. Previous longitudinal studies in hAHI have focused on the dynamics of pro-
14 inflammatory and antiviral cytokines and chemokines, particularly those immune markers
15 that exhibit increased levels and thereby part of the well-described cytokine storm^{9,20,21}.
16 Strikingly, our large-scale analysis of the blood plasma dynamics in hAHI indicated that the
17 differentially expressed proteins associated with ARS, VL, and disease progression was
18 overexpressed (here defined as *stormers*, in analogy with the cytokine storm) to a similar
19 extent as being underexpressed (here defined as *slumpers*). This warrants further studies and
20 it is possible that potential biomarkers and treatment targets may be identified also among
21 slumpers, as among stormers (which have been the main focus so far). Moreover, our study
22 expands beyond studies of acute phase and inflammatory proteins and includes proteins
23 involved in antigen presentation, cell transport, proteolysis, and cytoskeleton modulation
24 during hAHI. For example, vWF and FN1 were the most significantly elevated proteins
25 during hAHI (at peak viremia) and were both persistently elevated after hAHI. vWF reflects

1 persistent endothelial cell activation due to activation of the inflammation/coagulation
2 pathway, whereas FN1 is involved in cell adhesion, cell motility, opsonization, wound
3 healing, and maintenance of cell shape⁴⁰. FN1 also binds to HIV-1 gp120, which has been
4 shown to enhance complement interaction and infection of primary CD4+ T-cells⁴¹.
5 Moreover, HIV-1 has been shown to modulate the host cytoskeleton dynamics⁴². For
6 example, TTN, a protein that has been implicated in HIV-1 Gag subcellular trafficking,
7 showed increased levels one month after infection, whereas FGL1 levels, a marker of T-cell
8 activation/exhaustion, decreased at the onset of peak viremia, coinciding with the depletion of
9 CD4+ T-cells 3-4 weeks post-infection^{43,44}. Furthermore, HNRNPA2B1 levels at four weeks
10 after infection has been associated with virus setpoint levels, and previous studies have
11 suggested that HNRNPA2B1 can interact with viral components, have a critical role in
12 regulating the viral life cycle, and function as a viral DNA sensor initiating IFN
13 production^{45,46}.

14

15 We have previously shown that a stronger innate immune response in general, and an IP-10
16 activation in particular, is associated with the manifestation of ARS⁹. In the current study,
17 decreasing levels of ZYX, SCGB1A1, and PPBP during hAHI were associated with ARS. It
18 is possible that decreased levels of SCGB1A1, a pulmonary surfactant protein that influences
19 alveolar macrophage-mediated inflammation, may be linked to lung inflammation and
20 epithelial integrity in individuals with ARS^{34,47-49}. Moreover, the associations between
21 SCGB1A1 and ZYX expression and ARS supports previous suggestions of these proteins'
22 involvement in regulating innate immune responses triggered by viruses^{50,51}. Specifically,
23 ZYX binds to the mitochondrial antiviral signalling protein (MAVS) following recognition of
24 cytoplasmic double-stranded RNA by Retinoic acid-inducible gene I (RIG-I)-like receptors.

1 This latter interaction triggers the induction of type I interferon (IFN) expression, which
2 constitute the predominant immune response during hAHI.

3

4 Previous studies have suggested that certain cytokines, such as interleukin (IL)-15, IL-7, IL-
5 12p40, IL-12p70, and IFN-gamma, can predict 66% of the variation in viral set-point 12
6 months after infection⁵². In this study, viral controllers had increased levels of ARHGAP18
7 during hAHI. Interestingly, ARHGAP18 acts by converting Rho-type GTPases to an inactive
8 GDP-bound state³⁷. Rho GTPases play a crucial role in regulating actin cytoskeleton, and
9 HIV-1 and other viruses can induce specific Rho GTPase signalling to facilitate coreceptor
10 binding and transport of virus particles to sites of viral uptake by actin rearrangements⁵³. It is
11 therefore plausible that ARHGAP18, which suppresses F-actin polymerization by inhibiting
12 Rho, plays an important role in viral infectivity and fusion, and that reduced actin-dependent
13 binding of HIV-1 to CD4+ T-cells contributes to decreased viral load. Additionally, the levels
14 of the immune inflammation modulator ANXA1 was lower compared with pre-infection
15 levels among viral controllers compared with non-controllers. Indeed, ANXA1 has
16 previously been suggested as a potential therapeutic target towards gut immune dysfunction
17 in HIV-1 infection as a regulator of intestinal mucosal inflammation^{54,55}. Furthermore, a
18 gradual increase of ANXA1 expression in simian immunodeficiency virus (SIV) infection
19 has been suggested to facilitate disease progression by impairing inflammatory responses in
20 peripheral blood⁵⁴.

21

22 We also found that PRKCB was associated with a faster CD4+ T-cell decline. PRKCB
23 stimulates Nuclear Factor-kappa-B (NF- κ B) activation, which regulates B-cell activation, and
24 binds to the HIV-1 promoter, enhancing viral transcription. PRKCB is also involved in
25 cytoskeletal rearrangements necessary for virus entry, further implicating its importance in

1 HIV-1 replication, and the potential exacerbation of CD4+ T-cell decline. Finally, increased
2 levels of the host protease Hepsin was associated with a faster disease progression. This is in
3 line with previous observations that Hepsin suppresses the induction of type I interferons
4 (one of the major defence mechanisms of the human innate immune system towards virus
5 infections)⁵⁶.

6

7 The main strength of this study is the well-characterized samples collected before, during and
8 after hAHI. This enabled us to for the first time holistically assess the characteristics of the
9 plasma proteome dynamics in hyperacute HIV-1 infection at both the population and
10 individual patient level, and relative to pre-infection levels. Still, this study is not without
11 limitations. Platelet contamination during plasma separation has been proposed as a potential
12 bias in proteomic studies⁵⁷. Although consistent protocols were employed between cohort
13 sites, the possibility of human error impacting sample collection and handling cannot be fully
14 excluded. Moreover, it is possible that the depletion process may have inadvertently removed
15 some untargeted proteins. Still, the overall quantification of proteins increased 3-fold by this
16 approach, and importantly, the majority of proteins that were detected in both the neat and
17 depleted approaches showed similar results. In summary, this study provides new insights
18 into plasma protein dynamics associated with the complex virus-host interactions and
19 responses that take place when HIV-1 establishes infection in the human host and highlights a
20 similar role of both protein *stormers* and *slumpers* during hAHI. Several novel predictive and
21 prognostic biomarkers associated with ARS, VL responses, and disease progression were
22 identified. The potential implications of these findings are substantial and paves the way for
23 future investigations of diagnostic and prognostic utilities of these biomarkers. Furthermore,
24 our study underscores the need for continued basic research of HIV-1 infection, and other

- 1 virus infections, to identify biomarkers with potential in early diagnosis, novel and improved
- 2 treatment strategies of viruses.

1 REFERENCES

- 2 1 Zhong, W. *et al.* Whole-genome sequence association analysis of blood proteins in a
3 longitudinal wellness cohort. *Genome Med* **12**, 53, doi:10.1186/s13073-020-00755-0
4 (2020).
- 5 2 Captur, G. *et al.* Plasma proteomic signature predicts who will get persistent
6 symptoms following SARS-CoV-2 infection. *eBioMedicine* **85**,
7 doi:10.1016/j.ebiom.2022.104293 (2022).
- 8 3 Palma Medina, L. M. *et al.* Targeted plasma proteomics reveals signatures
9 discriminating COVID-19 from sepsis with pneumonia. *Respiratory Research* **24**, 62,
10 doi:10.1186/s12931-023-02364-y (2023).
- 11 4 Al-Nesf, M. A. Y. *et al.* Prognostic tools and candidate drugs based on plasma
12 proteomics of patients with severe COVID-19 complications. *Nature*
13 *Communications* **13**, 946, doi:10.1038/s41467-022-28639-4 (2022).
- 14 5 Cohen, M. S., Shaw, G. M., McMichael, A. J. & Haynes, B. F. Acute HIV-1
15 Infection. *New England Journal of Medicine* **364**, 1943-1954,
16 doi:10.1056/NEJMra1011874 (2011).
- 17 6 McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The
18 immune response during acute HIV-1 infection: clues for vaccine development.
19 *Nature Reviews Immunology* **10**, 11-23, doi:10.1038/nri2674 (2010).
- 20 7 Ndhlovu, Z. M. *et al.* Magnitude and Kinetics of CD8+ T Cell Activation during
21 Hyperacute HIV Infection Impact Viral Set Point. *Immunity* **43**, 591-604,
22 doi:10.1016/j.immuni.2015.08.012 (2015).
- 23 8 Ndhlovu, Z. M. *et al.* Augmentation of HIV-specific T cell function by immediate
24 treatment of hyperacute HIV-1 infection. *Sci Transl Med* **11**,
25 doi:10.1126/scitranslmed.aau0528 (2019).
- 26 9 Hassan, A. S. *et al.* A Stronger Innate Immune Response During Hyperacute Human
27 Immunodeficiency Virus Type 1 (HIV-1) Infection Is Associated With Acute
28 Retroviral Syndrome. *Clinical Infectious Diseases* **73**, 832-841,
29 doi:10.1093/cid/ciab139 (2021).
- 30 10 Robb, M. L., Eller, L. A. & Rolland, M. Acute HIV-1 Infection in Adults in East
31 Africa and Thailand. *The New England journal of medicine* **375**, 1195,
32 doi:10.1056/NEJMc1609157 (2016).
- 33 11 Sanders, E. J. *et al.* Differences in acute retroviral syndrome by HIV-1 subtype in a
34 multicentre cohort study in Africa. *AIDS (London, England)* **31**, 2541-2546,
35 doi:10.1097/qad.0000000000001659 (2017).
- 36 12 Tindall, B. *et al.* Characterization of the acute clinical illness associated with human
37 immunodeficiency virus infection. *Arch Intern Med* **148**, 945-949 (1988).
- 38 13 Kazer, S. W., Walker, B. D. & Shalek, A. K. Evolution and Diversity of Immune
39 Responses during Acute HIV Infection. *Immunity* **53**, 908-924,
40 doi:10.1016/j.immuni.2020.10.015 (2020).
- 41 14 Brenchley, J. M. *et al.* CD4+ T cell depletion during all stages of HIV disease occurs
42 predominantly in the gastrointestinal tract. *J Exp Med* **200**, 749-759,
43 doi:10.1084/jem.20040874 (2004).


- 1 15 Levesque, M. C. *et al.* Polyclonal B cell differentiation and loss of gastrointestinal
2 tract germinal centers in the earliest stages of HIV-1 infection. *PLoS Med* **6**,
3 e1000107, doi:10.1371/journal.pmed.1000107 (2009).
- 4 16 Lavreys, L. *et al.* Higher set point plasma viral load and more-severe acute HIV type
5 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
6 *Clin Infect Dis* **42**, 1333-1339, doi:10.1086/503258 (2006).
- 7 17 Lefrère, J. J. *et al.* The risk of disease progression is determined during the first year
8 of human immunodeficiency virus type 1 infection. *J Infect Dis* **177**, 1541-1548,
9 doi:10.1086/515308 (1998).
- 10 18 Lindbäck, S. *et al.* Viral dynamics in primary HIV-1 infection. Karolinska Institutet
11 Primary HIV Infection Study Group. *AIDS (London, England)* **14**, 2283-2291,
12 doi:10.1097/00002030-200010200-00009 (2000).
- 13 19 Deeks, S. G. *et al.* Research priorities for an HIV cure: International AIDS Society
14 Global Scientific Strategy 2021. *Nature Medicine* **27**, 2085-2098,
15 doi:10.1038/s41591-021-01590-5 (2021).
- 16 20 Muema, D. M. *et al.* Association between the cytokine storm, immune cell dynamics,
17 and viral replicative capacity in hyperacute HIV infection. *BMC Medicine* **18**,
18 doi:10.1186/s12916-020-01529-6 (2020).
- 19 21 Stacey, A. R. *et al.* Induction of a striking systemic cytokine cascade prior to peak
20 viremia in acute human immunodeficiency virus type 1 infection, in contrast to more
21 modest and delayed responses in acute hepatitis B and C virus infections. *J Virol* **83**,
22 3719-3733, doi:10.1128/jvi.01844-08 (2009).
- 23 22 Deutsch, E. W. *et al.* Advances and Utility of the Human Plasma Proteome. *Journal*
24 *of Proteome Research* **20**, 5241-5263, doi:10.1021/acs.jproteome.1c00657 (2021).
- 25 23 Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**,
26 1260419, doi:10.1126/science.1260419 (2015).
- 27 24 Kamali, A. *et al.* Creating an African HIV clinical research and prevention trials
28 network: HIV prevalence, incidence and transmission. *PloS one* **10**, e0116100,
29 doi:10.1371/journal.pone.0116100 (2015).
- 30 25 Price, M. A. *et al.* Cohort Profile: IAVI's HIV epidemiology and early infection
31 cohort studies in Africa to support vaccine discovery. *International journal of*
32 *epidemiology* **50**, 29-30, doi:10.1093/ije/dyaa100 (2021).
- 33 26 Dong, K. L. *et al.* Detection and treatment of Fiebig stage I HIV-1 infection in young
34 at-risk women in South Africa: a prospective cohort study. *The lancet. HIV* **5**, e35-
35 e44, doi:10.1016/s2352-3018(17)30146-7 (2018).
- 36 27 Bassett, I. V. *et al.* Screening for acute HIV infection in South Africa: finding acute
37 and chronic disease. *HIV Med* **12**, 46-53, doi:10.1111/j.1468-1293.2010.00850.x
38 (2011).
- 39 28 Fiebig, E. W. *et al.* Dynamics of HIV viremia and antibody seroconversion in plasma
40 donors: implications for diagnosis and staging of primary HIV infection. *AIDS*
41 *(London, England)* **17**, 1871-1879, doi:10.1097/00002030-200309050-00005 (2003).
- 42 29 Tu, C. *et al.* Depletion of Abundant Plasma Proteins and Limitations of Plasma
43 Proteomics. *Journal of Proteome Research* **9**, 4982-4991, doi:10.1021/pr100646w
44 (2010).

- 1 30 Consortium, T. U. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic*
2 *Acids Research* **51**, D523-D531, doi:10.1093/nar/gkac1052 (2022).
- 3 31 Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C. & al., e. Tissue-based map
4 of the human proteome. **347**, 1260419, doi:doi:10.1126/science.1260419 (2015).
- 5 32 Arthur, L. *et al.* Cellular and plasma proteomic determinants of COVID-19 and non-
6 COVID-19 pulmonary diseases relative to healthy aging. *Nature Aging* **1**, 535-549,
7 doi:10.1038/s43587-021-00067-x (2021).
- 8 33 Wójtowicz, A. *et al.* Zyxin mediation of stretch-induced gene expression in human
9 endothelial cells. *Circ Res* **107**, 898-902, doi:10.1161/circresaha.110.227850 (2010).
- 10 34 Xu, M., Yang, W., Wang, X. & Nayak, D. K. Lung Secretoglobin Scgb1a1 Influences
11 Alveolar Macrophage-Mediated Inflammation and Immunity. *Frontiers in*
12 *Immunology* **11**, doi:10.3389/fimmu.2020.584310 (2020).
- 13 35 Cohen, A. B., Stevens, M. D., Miller, E. J., Atkinson, M. A. & Mullenbach, G.
14 Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-
15 treated human platelets. *Am J Physiol* **263**, L249-256,
16 doi:10.1152/ajplung.1992.263.2.L249 (1992).
- 17 36 NIH. *HIV-1 Human Interaction Database*,
18 <<https://www.ncbi.nlm.nih.gov/genome/viruses/retroviruses/hiv-1/interactions/>>
19 (2023).
- 20 37 Maeda, M. *et al.* ARHGAP18, a GTPase-activating protein for RhoA, controls cell
21 shape, spreading, and motility. *Mol Biol Cell* **22**, 3840-3852, doi:10.1091/mbc.E11-
22 04-0364 (2011).
- 23 38 Vago, J. P. *et al.* Proresolving Actions of Synthetic and Natural Protease Inhibitors
24 Are Mediated by Annexin A1. *The Journal of Immunology* **196**, 1922-1932,
25 doi:10.4049/jimmunol.1500886 (2016).
- 26 39 Younas, M. *et al.* Microbial Translocation Is Linked to a Specific Immune Activation
27 Profile in HIV-1-Infected Adults With Suppressed Viremia. *Frontiers in Immunology*
28 **10**, doi:10.3389/fimmu.2019.02185 (2019).
- 29 40 Schapkaitz, E., Libhaber, E., Jacobson, B. F., Meiring, M. & Büller, H. R. von
30 Willebrand factor propeptide-to-antigen ratio in HIV-infected pregnancy: Evidence of
31 endothelial activation. *Journal of Thrombosis and Haemostasis* **19**, 3168-3176,
32 doi:<https://doi.org/10.1111/jth.15502> (2021).
- 33 41 Greco, G., Pal, S., Pasqualini, R. & Schnapp, L. M. Matrix Fibronectin Increases HIV
34 Stability and Infectivity1. *The Journal of Immunology* **168**, 5722-5729,
35 doi:10.4049/jimmunol.168.11.5722 (2002).
- 36 42 Naghavi, M. H. & Goff, S. P. Retroviral proteins that interact with the host cell
37 cytoskeleton. *Curr Opin Immunol* **19**, 402-407, doi:10.1016/j.coi.2007.07.003 (2007).
- 38 43 Cooper, J. *et al.* Filamin A Protein Interacts with Human Immunodeficiency Virus
39 Type 1 Gag Protein and Contributes to Productive Particle Assembly *<sup>
40 </sup>. *Journal of Biological Chemistry* **286**, 28498-28510,
41 doi:10.1074/jbc.M111.239053 (2011).
- 42 44 Wang, J. *et al.* Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of
43 LAG-3. *Cell* **176**, 334-347.e312, doi:10.1016/j.cell.2018.11.010 (2019).

- 1 45 Bhattarai, K. & Holcik, M. Diverse roles of heterogeneous nuclear ribonucleoproteins
2 in viral life cycle. *Frontiers in Virology* **2**, doi:10.3389/fviro.2022.1044652 (2022).
- 3 46 Zhang, X., Flavell, R. A. & Li, H.-B. hnRNPA2B1: a nuclear DNA sensor in antiviral
4 immunity. *Cell Research* **29**, 879-880, doi:10.1038/s41422-019-0226-8 (2019).
- 5 47 Pang, M. *et al.* Recombinant CC16 protein inhibits the production of pro-
6 inflammatory cytokines via NF- κ B and p38 MAPK pathways in LPS-activated
7 RAW264.7 macrophages. *Acta Biochimica et Biophysica Sinica* **49**, 435-443,
8 doi:10.1093/abbs/gmx020 (2017).
- 9 48 Dierynck, I., Bernard, A., Roels, H. & De Ley, M. Potent inhibition of both human
10 interferon-gamma production and biologic activity by the Clara cell protein CC16. *Am*
11 *J Respir Cell Mol Biol* **12**, 205-210, doi:10.1165/ajrcmb.12.2.7865218 (1995).
- 12 49 Xu, M., Yang, W., Wang, X. & Nayak, D. K. Lung Secretoglobin Scgb1a1 Influences
13 Alveolar Macrophage-Mediated Inflammation and Immunity. *Frontiers in*
14 *immunology* **11**, 584310, doi:10.3389/fimmu.2020.584310 (2020).
- 15 50 Huang, S. *et al.* SOCS Proteins Participate in the Regulation of Innate Immune
16 Response Caused by Viruses. *Front Immunol* **11**, 558341,
17 doi:10.3389/fimmu.2020.558341 (2020).
- 18 51 Kouwaki, T. *et al.* Zyxin stabilizes RIG-I and MAVS interactions and promotes type I
19 interferon response. *Sci Rep* **7**, 11905, doi:10.1038/s41598-017-12224-7 (2017).
- 20 52 Roberts, L. *et al.* Plasma cytokine levels during acute HIV-1 infection predict HIV
21 disease progression. *AIDS (London, England)* **24**, 819-831,
22 doi:10.1097/QAD.0b013e3283367836 (2010).
- 23 53 Van den Broeke, C., Jacob, T. & Favoreel, H. W. Rho'ing in and out of cells: viral
24 interactions with Rho GTPase signaling. *Small GTPases* **5**, e28318,
25 doi:10.4161/sgtp.28318 (2014).
- 26 54 Sena, A. A. *et al.* Divergent Annexin A1 expression in periphery and gut is associated
27 with systemic immune activation and impaired gut immune response during SIV
28 infection. *Sci Rep* **6**, 31157, doi:10.1038/srep31157 (2016).
- 29 55 Babbitt, B. A. *et al.* Annexin A1 regulates intestinal mucosal injury, inflammation,
30 and repair. *J Immunol* **181**, 5035-5044, doi:10.4049/jimmunol.181.7.5035 (2008).
- 31 56 Hsin, F., Hsu, Y. C., Tsai, Y. F., Lin, S. W. & Liu, H. M. The transmembrane serine
32 protease hepsin suppresses type I interferon induction by cleaving STING. *Sci Signal*
33 **14**, doi:10.1126/scisignal.abb4752 (2021).
- 34 57 Geyer, P. E. *et al.* Plasma Proteome Profiling to detect and avoid sample-related
35 biases in biomarker studies. *EMBO Molecular Medicine* **11**,
36 doi:10.15252/emmm.201910427 (2019).
37


1 FIGURES

2 Fig. 1 | Characteristics of the study participants.






3

1 **Fig. 2 | Acute HIV-1 infection alters the human plasma proteome.**




c. Decreased




1 **Fig. 3 | Decreased levels of Zyxin, Secretoglobin family 1A member 1 and Pro-platelet basic protein two weeks post HIV-1 infection is associated with having ARS.**

2 **basic protein two weeks post HIV-1 infection is associated with having ARS.**




3

1 **Fig. 4 | ARHGAP18, ANXA1 and LBP could have key roles in HIV-1 viral control.**




1 **Fig. 5 | HPN, PRKCB and ITGB3 are associated with increased risk of disease**
2 **progression.**



3

1 **Fig. 6 | Longitudinal dynamics during hyperacute HIV-1 infection of key differentially**
 2 **expressed proteins associated with ARS, viral load and disease progression.**



3

4

1 **FIGURE LEGENDS**

2 **Fig. 1 | Characteristics of the study participants.** The flowchart illustrates the longitudinal
3 sampling approach adopted in the study and outlines the workflow for processing proteomic
4 data. A total of 54 individuals from two geographical regions contributed three matched
5 each. These samples underwent plasma preparation with and without depletion of top 14
6 abundant proteins, followed by DIA/SWATH LC-MS/MS analysis, and subsequent
7 computational analyses. Arrows denote the flow of samples and processing steps.
8 Abbreviations: SA, South Africa; KE, Kenya; DIA, data-independent acquisition; SWATH,
9 sequential window acquisition of all theoretical mass spectra; LC-MS/MS, liquid
10 chromatography coupled to tandem mass spectrometry.

11

12 **Fig. 2 | Acute HIV-1 infection alters the human plasma proteome. a,** Longitudinal protein
13 expression profiles were investigated during hAHI using a dendrogram constructed through
14 hierarchical clustering with complete linkage. A comprehensive analysis of 83,643 protein
15 combination values from all three time points was conducted across 54 study participants,
16 resulting in a total of 1336 profiles. To identify the optimal clusters representing the
17 longitudinal expression profiles for different groups, the elbow method was employed,
18 leading to identification of six distinct clusters. These clusters were color-coded and plotted,
19 with the x-axis denoting the visit number and the y-axis representing the scaled log-intensity
20 per patient. **b,** Bar plot illustrating the comparison in the number of differentially expressed
21 proteins across visit differences. The height of each bar corresponds to the number of proteins
22 while the bar colour varies depending on the visit difference. **c,** Forest plots depicting
23 differentially expressed proteins at two weeks, one-month post-infection, while also
24 accounting for pre-infection levels (V1-V0 and V2-V0, respectively), as well as the
25 difference between visit 2 and visit 1. The plot displays results from linear mixed model

1 analysis, with visit number as a categorical variable ($\log I \sim \text{visit} + (1|\text{patientid})$). The
2 horizontal line represents the confidence interval for the effect size of each protein
3 significantly differentially expressed in both cohorts (depicted in grey for the Durban cohort
4 and maroon for the IAVI cohort). The circle and triangle denote the overall $\log_2\text{FC}$ /effect
5 size for depleted or neat plasma, respectively. Proteins with three or more horizontal lines
6 indicate that those proteins were detected in both depleted and neat plasma ($p < 0.005$;
7 $q < 0.05$). Upregulated proteins in all comparisons are shown on the right side of plot,
8 separated by a vertical dotted grey line, while downregulated proteins are on the left side. **d,e**,
9 circos plots visualising the differentially expressed proteins from different visit differences in
10 a circular layout. The lower ring represents the GO-biological processes associated with the
11 proteins belong to, with each process color-coded for easy identification. The upper rings
12 depict specific classification of these proteins, with proteins secreted in blood shown in
13 orange and the tissue leakage proteins shown in grey.

14

15 **Fig. 3 | Decreased levels of proteins ZYX, SCGB1 and PPBP two weeks post HIV-1**
16 **infection is associated with having ARS. a**, Flow chart representing the total number of
17 samples used in ARS classification and the exclusion criteria. **b**, Bar graph comparing the
18 distribution of AHI symptoms between volunteers that were defined to be with and without
19 ARS (N=33). ARS was defined based on 11 AHI symptoms, and unobserved linkages
20 between symptoms using Latent Class Analysis. Incremental latent group models were
21 assessed to predict the goodness of fit. The model with two latent groups was the best fit,
22 with the lowest BIC value (660.5) compared to three (678.6), four (699.2), or five (714.7)
23 groups. Study participants were grouped based on their predicted posterior probabilities into
24 those with ARS (N=20/33 (60%)) and those without ARS (13/33 (40%)). **c**, Box plot
25 displaying results of the cross-validated performance measure (accuracy) for the ARS PLS-

1 DA models. These models were trained to predict ARS “Yes” or “No” and evaluated in 10 5-
2 fold cross-validations. For each test set, the performance measures accuracy was computed.
3 Models were constructed based on the following datasets: V0 + V1 + V2; V0 + V1-V0 + V2-
4 V0; V1 + V2; V1-V0 + V2-V0; V1-V0; and V2-V0. **d**, Score plot based on the V1-V0 + V2-
5 V0 dataset (with the highest accuracy value) from (c), indicating the group membership of
6 each sample. There was clear discrimination between the ARS-No (orange) and the ARS-Yes
7 (green) samples on the first (x-axis) and second components (y-axis). Axis labels indicate the
8 percentage of variation explained per component. **e**, Boxplot showing the variable importance
9 in projection (VIP) scores in the PLS-DA model based on V1-V0 for each protein. VIP score
10 summarizes the contribution a variable (protein) makes to the model. This plot identifies the
11 most important proteins for the classification of ARS Yes or No. Proteins with high VIP are
12 more important in providing class separation. Black points represent the full model and the
13 boxplot show distribution for 10 cross-validation models. **f**, Forest plot displaying the
14 proteins associated with ARS using linear mixed models. **g**, Heatmap of proteins associated
15 with ARS based on hierarchical clustering of the V1-V0 and V2-V0 expression of the
16 selected proteins. **h**, Pirate plots showing the V1-V0 protein expression for the top proteins
17 between those with and without ARS. **i**, Table representing the longitudinal protein
18 expression profiles for the top proteins associated with ARS. For each profile and protein, the
19 number (%) of patients with or without ARS were recorded. Abbreviations: ARS, Acute
20 retroviral syndrome; PLS-DA, Partial Least Squares Discriminant analysis; V, visit; V1-V0,
21 difference between visit V1 and V0; V2-V0, difference between visit V2 and V0; V2-V1,
22 difference between visit V2 and V1; Log2FC, log 2-fold change. The asterisk (*) appended to
23 the end of certain protein names indicates proteins detected in neat plasma, while proteins
24 without an asterisk were identified in depleted plasma samples.

25

1 **Fig. 4 | ARHGAP18, ANXA1, and PDLIM1 was associated with HIV-1 control.**

2 **a**, Flow chart illustrating the total number of samples used in viral control classification,
3 along with the exclusion criteria. **b**, A plot displaying the viral load measured for all the 54
4 participants in the first 100 days since EDI. **c**, Dendrogram showcasing complete linkage
5 hierarchical clustering of viral load profiles. Euclidean distances computed from the cubic
6 spline predicted viral load at evenly spread (on transformed scale) time points were used for
7 clustering. The optimal number of clusters was determined using the Silhouette value, and the
8 clustering significance was calculated using multiscale bootstrap resampling. Viral load
9 clusters were based on time 1-12 months (30 to 364 days). Two distinct groups were
10 classified: No viral control (in green) and sustained viral control (in brown). **d**, Plot
11 representing the cubic spline predicted viral load at evenly spread time points. The
12 differentiation between the two viral control groups occurred at a viral load threshold of
13 10,000 copies/ml. **e**, Heatmap illustrating associations between viral control and various
14 demographic parameters and ARS symptoms. **f**, Forest plot depicting proteins associated with
15 viral control (clusters based on 1-12 months [complete linkage, Euclidean]) at visit difference
16 V1-V0, V2-V0, and V2-V1. The asterisk (*) appended to certain protein names indicates
17 proteins quantitated from neat plasma, while proteins without an asterisk were identified in
18 depleted plasma samples. Abbreviations: VL, viral load; DC, discordant couple; HET,
19 heterosexual; MSM, men who have sex with men; V, visit. Asterisk (*) indicates proteins
20 quantitated from neat plasma.

21

22 **Fig. 5 | HPN, PRKCB and ITGB3 are associated with increased risk of disease**

23 **progression. a**, A forest plot illustrating proteins associated with the time to CD4+ T-cell
24 counts <500 cells/ μ l, with their corresponding hazard ratios adjusting for age, site of
25 collection, sex and HIV-1 subtype. Protein expressions are based on visit differences V1-V0,

1 V2-V0, and V2-V1 with p-values <0.005 , Cox regression models. Asterisk (*) indicates
2 proteins quantitated from neat plasma.

3

4 **Fig. 6 | Longitudinal dynamics during hyperacute HIV-1 infection of key differentially**
5 **expressed proteins associated with ARS, viral load and disease progression.** This
6 schematic illustrates the temporal changes in expression for proteins associated with ARS,
7 viral load, and disease progression during acute phase of HIV-1 infection. Protein expression
8 levels were assessed both before infection, and within the two to six weeks following
9 infection in the 54 study participants. Participants were categorized into subgroups based on
10 various outcomes, including ARS (presence or absence), viral control status (controllers or
11 non-controllers), and the rate of disease progression (fast or slow). The x-axis of the graph
12 represents the time in days following infection when plasma samples were collected, while
13 the y-axis represents the mean protein expression levels relative to the pre-infection baseline.
14 Key proteins associated with ARS, viral control and disease progression are depicted using
15 smoothed lines generated through local regression plotting with a span of 1.5. The selected
16 proteins represented the top proteins associated with ARS, viral load, and disease progression
17 To enhance clarity and highlight distinctive patterns, proteins with similar dynamics in the
18 group comparisons were excluded.

19

1 **METHODS**

2 **Study subjects and ethical considerations**

3 Data and samples for this study were obtained from sub-Saharan African (sSA) adults (≥ 18
4 years old) enrolled in acute and early HIV-1 infection studies. East African volunteers were
5 enrolled in Kenya, Rwanda, and Zambia between 2006 and 2011 under IAVI's protocols B
6 and C, while South African volunteers were enrolled in Durban between 2007 and 2014
7 under the FRESH (Females Rising through Education Support and Health) and HIV
8 Pathogenesis Programme (HPP) acute infection cohorts¹⁻⁴. Baseline variables such as date of
9 birth, sex, HIV-1 RNA, HIV-1 p24 antigen, and antibody test results, date of HIV-1
10 diagnosis, transmission risk group, antiretroviral treatment start date, CD4+ and CD8+ T-cell
11 dynamics, and AHI symptoms were collected. All study participants provided written
12 informed consent for the use of their samples for biomedical research, and all sites received
13 approvals from respective country-specific ethics review boards¹⁻⁴. Additionally, all data and
14 samples were de-identified and anonymised to protect the privacy of the volunteers.

15
16 Eligibility for the study included hyperacute HIV-1 infection (hAHI), which was defined as
17 HIV-1 antibody negative and RNA positive (Fiebig stage I) or p24 antigen-positive (Fiebig
18 stage II), corresponding to the period from onset of plasma viremia to peak viral load⁵⁻⁸.
19 Matched longitudinal plasma samples were collected at three different visits: (i) visit 0, which
20 was between 22 and 120 days before the estimated date of infection, EDI), (ii) visit 1 which
21 was between 10-14 days post EDI; and (iii) visit 2 which was between 15-42 days post EDI.
22 EDI was defined either as the midpoint between the date of the last negative and first positive
23 HIV antibody test, or 14 days before the date of the first positive p24 antigen test (with a
24 negative antibody test), or 10 days before the date of the first PCR-positive test (with a
25 negative antibody or p24 antigen detection).

1

2 **Sample preparation for LC-MS/MS analysis**

3 Blood plasma samples archived at -80°C were obtained for liquid chromatography with
4 tandem mass spectrometry (LC-MS/MS). Both neat and depleted plasma were analysed to
5 increase the number of detected proteins. Depletion refers to removal of the top 14 highly
6 abundant proteins before protein quantification. Details of the specific plasma preparation,
7 LC-MS/MS run conditions, instrumentation and spectral library generation have been
8 documented in supplementary methods.

9

10 **DIA/SWATH-MS Targeted Data Extraction**

11 DIA data files were analysed using Spectronaut 15.1 (Biognosys, Schlieren, Switzerland),
12 against the spectral library using the BGS factory default settings. The identifications were
13 filtered at a false discovery rate (FDR) of 1% at both peptide and protein levels. Spectronaut
14 used retention time prediction based on iRT, the m/z dimension in the SWATH-MS data,
15 mass accuracy, and isotopic distribution of fragment ions to identify a peptide. All available
16 transitions were extracted for each targeted peptide, together with their corresponding decoy-
17 transition groups, which were generated by pseudo-reversing the sequence of the targeted
18 peptides.

19

20 **Protein quantification and data pre-processing**

21 To derive protein abundances, peptide precursor and fragment ion intensities were used, and
22 the MaxLFQ algorithm (implemented in *iq* R Package) was employed. This algorithm
23 combined multiple peptide ratios to derive optimal protein ratios between pairs of samples,
24 ensuring accuracy and reliability of the data^{9,10}. The global distribution of the protein signals
25 was assessed to identify poor quality or low-intensity data. Protein with $>80\%$ missing values

1 across samples were removed, and factors such as time of sample collection, date of
2 infection, and date of MS data acquisition were assessed to identify any correlations with
3 missingness. Missing values were imputed by replacing them with a randomly chosen value
4 between one and the minimum global raw intensity value of the protein. The data matrix was
5 then analysed by NormalyzerDE to identify the normalisation method with the least variance
6 in the data, and the normalization was performed based on the results obtained from
7 NormalyzerDE¹¹.

8

9 **Statistical Analysis**

10 *Differential expression analysis*

11 To identify differentially expressed proteins (DEPs, proteins that changed over time), a
12 compressed and visualized protein data using principal component analysis (PCA) for several
13 variables including site of collection, HIV-1 subtype, age, and visit number was used. In the
14 following differential analyses across different groups, adjustments were made for principal
15 components (PCs) 1 and 2. Next, the association of each protein with visit number using a
16 linear mixed model with a random intercept for each study participant was tested. A global
17 analysis of variance (ANOVA) test was then conducted to identify the proteins that changed
18 between visits, and *post hoc* tests were performed to determine when the changes occurred.
19 For each protein, global p-values were obtained by likelihood ratio tests of the full model
20 with the effect in question against the model without the effect. Multiple testing correction
21 using the Benjamini-Hochberg's FDR method with a significance threshold of 5% FDR was
22 applied. A fixed p-value cut-off of $p < 0.005$ for all tests was also applied. The upregulated and
23 downregulated DEPs at different visits were filtered using $p < 0.005$ and plotted in Volcano or
24 Forest plots with 95% CI for log₂ fold change.

25

1 *Enrichment or pathway analysis*

2 Protein classifications and annotations were based on subcellular location annotations from
3 the uniProt database, which denotes location and the topology of the mature protein in the
4 cell, and the human protein atlas (HPA) resource^{12,13}. To determine whether a set of
5 differentially expressed proteins and their gene ontology (GO) biological processes were
6 statistically different between two biological states (activated and suppressed), enrichment
7 analysis was conducted using Clusterprofiler¹⁴. The statistical significance of the over-
8 representation was determined based the Fisher's exact test and Bonferroni's FDR ($p < 0.05$).
9 The protein list from both neat and depleted plasma was used as the custom background. The
10 top ten enriched terms, along with their respective p-values, were determined.

11

12 *Tissue damage analysis*

13 To evaluate tissue-specific protein expression, a previously established dataset of tissue-
14 enriched transcriptional signatures derived from the Genotype-Tissue Expression (GTEx)
15 project was utilized¹⁵. The GTEx read counts were transformed into trimmed values and
16 normalized to z-scores for each gene across tissues. Genes with a z-score exceeding three
17 were classified as tissue-enriched. Subsequently, this list of tissue-enriched proteins was
18 employed as the reference database for conducting enrichment analysis with all quantified
19 proteins using Clusterprofiler.

20

21 *Acute Retroviral Syndrome (ARS)*

22 Symptoms during acute HIV infection (AHI) were not part of the study protocol for the
23 FRESH and HPP cohorts and were therefore only recorded for IAVI volunteers using a
24 standardized questionnaire 2-6 weeks after the estimated date of infection¹⁶. ARS was
25 defined based on 11 symptoms, including fever, headache, myalgia, fatigue, anorexia,

1 pharyngitis, diarrhoea, night sweats, skin rash, lymphadenopathy, oral ulcers. Previous
2 studies have used different definitions for ARS, such as reporting any symptom, ≥ 2
3 symptoms, ≥ 3 symptoms, or a combination of fever with other symptom(s)¹⁷. However,
4 discrete classification methods may not account for unobserved linkages between symptoms.
5 To address this limitation, latent class analysis (LCA), a structural equation modelling
6 approach, was used to group volunteers based on the number of AHI symptoms and other
7 unobserved linkages. To determine if the proteomic signature could predict or identify ARS,
8 supervised learning approaches, including Partial Least-Squares Discriminant Analysis (PLS-
9 DA, examining all proteins simultaneously) and linear mixed models (considering each
10 protein separately) were used to analyse the proteomic data from all time points and the delta
11 values (protein value change between time points) for each study participant.

12

13 *Disease progression*

14 Disease progression was measured using two endpoints: viral control and CD4+ T-cell
15 decline. For viral control, viral load measurements were taken on various days for each study
16 participant. To compare the viral load profiles between participants, curve fittings were used.
17 All VL measurements from the estimated date of infection until before the start of
18 antiretroviral treatment (ART) were used. VL measurements were log₁₀-transformed, and an
19 optimal smoothing parameter was calculated using leave-one-out cross-validation. A cubic
20 smoothing spline was then fitted separately for each participant, and the Euclidean distance
21 between VL curves was calculated at evenly distributed time points. Participants with
22 observations at the beginning and end of a given time interval were clustered based on
23 Euclidean distance using hierarchical clustering. The optimal number of clusters was
24 determined using the Silhouette method, and clusters were based on a period of 1-12 months.

25

1 For CD4+ T-cell decline, a time-to-event analysis using an absolute CD4+ T-cell count of
2 less than 500 from six weeks after EDI as the event was conducted. In addition, the log-rank
3 test was used to assess differences between covariates ($p < 0.05$ was considered statistically
4 significant). The Cox proportional hazards model, adjusting for age, sex, cohort was used to
5 determine the association between each plasma protein and the risk of disease progression.
6 Follow-up time was censored at the initiation of antiretroviral treatment (ART) or the last
7 observed time point if ART was not initiated. The results was presented as Hazard ratios with
8 95% confidence intervals (CIs), and Kaplan-Meier time-to-event curves.

9

10 **Data availability**

11 Proteomics data supporting findings in this study have been deposited to the
12 ProteomeXchange Consortium via PRoteomics IDentifications (PRIDE) partner repository
13 with the dataset identifier PXD042850
14 (<https://www.ebi.ac.uk/pride/archive/projects/PXD042850>).

15

16 **Code availability**

17 All original code has been deposited and can be assessed at:
18 <https://github.com/NBISweden/SMS-5800-HIV> upon request.

1 METHOD REFERENCES

- 2 1 Kamali, A. et al. Creating an African HIV clinical research and prevention trials
3 network: HIV prevalence, incidence and transmission. *PloS one* 10, e0116100,
4 doi:10.1371/journal.pone.0116100 (2015).
- 5 2 Price, M. A. et al. Cohort Profile: IAVI's HIV epidemiology and early infection
6 cohort studies in Africa to support vaccine discovery. *International journal of*
7 *epidemiology* 50, 29-30, doi:10.1093/ije/dyaa100 (2021).
- 8 3 Dong, K. L. et al. Detection and treatment of Fiebig stage I HIV-1 infection in young
9 at-risk women in South Africa: a prospective cohort study. *The lancet. HIV* 5, e35-
10 e44, doi:10.1016/s2352-3018(17)30146-7 (2018).
- 11 4 Bassett, I. V. et al. Screening for acute HIV infection in South Africa: finding acute
12 and chronic disease. *HIV Med* 12, 46-53, doi:10.1111/j.1468-1293.2010.00850.x
13 (2011).
- 14 5 Cohen, M. S., Shaw, G. M., McMichael, A. J. & Haynes, B. F. Acute HIV-1
15 Infection. *New England Journal of Medicine* 364, 1943-1954,
16 doi:10.1056/NEJMra1011874 (2011).
- 17 6 McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The
18 immune response during acute HIV-1 infection: clues for vaccine development.
19 *Nature Reviews Immunology* 10, 11-23, doi:10.1038/nri2674 (2010).
- 20 7 Ndhlovu, Z. M. et al. Magnitude and Kinetics of CD8+ T Cell Activation during
21 Hyperacute HIV Infection Impact Viral Set Point. *Immunity* 43, 591-604,
22 doi:10.1016/j.immuni.2015.08.012 (2015).
- 23 8 Ndhlovu, Z. M. et al. Augmentation of HIV-specific T cell function by immediate
24 treatment of hyperacute HIV-1 infection. *Sci Transl Med* 11,
25 doi:10.1126/scitranslmed.aau0528 (2019).
- 26 9 Cox, J. et al. Accurate proteome-wide label-free quantification by delayed
27 normalization and maximal peptide ratio extraction, termed MaxLFQ. *Molecular &*
28 *cellular proteomics* : MCP 13, 2513-2526, doi:10.1074/mcp.M113.031591 (2014).
- 29 10 Pham, T. V., Henneman, A. A. & Jimenez, C. R. iq: an R package to estimate relative
30 protein abundances from ion quantification in DIA-MS-based proteomics.
31 *Bioinformatics* 36, 2611-2613, doi:10.1093/bioinformatics/btz961 (2020).
- 32 11 Willforss, J., Chawade, A. & Levander, F. NormalyzerDE: Online Tool for Improved
33 Normalization of Omics Expression Data and High-Sensitivity Differential
34 Expression Analysis. *Journal of Proteome Research* 18, 732-740,
35 doi:10.1021/acs.jproteome.8b00523 (2019).
- 36 12 Consortium, T. U. UniProt: the Universal Protein Knowledgebase in 2023. *Nucleic*
37 *Acids Research* 51, D523-D531, doi:10.1093/nar/gkac1052 (2022).
- 38 13 Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. *Science* 347,
39 1260419, doi:10.1126/science.1260419 (2015).
- 40 14 Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics
41 data. *The Innovation* 2, 100141, doi:https://doi.org/10.1016/j.xinn.2021.100141
42 (2021).

- 1 15 Arthur, L. et al. Cellular and plasma proteomic determinants of COVID-19 and non-
2 COVID-19 pulmonary diseases relative to healthy aging. *Nature Aging* 1, 535-549,
3 doi:10.1038/s43587-021-00067-x (2021).
- 4 16 Sanders, E. J. et al. Differences in acute retroviral syndrome by HIV-1 subtype in a
5 multicentre cohort study in Africa. *AIDS (London, England)* 31, 2541-2546,
6 doi:10.1097/qad.0000000000001659 (2017).
- 7 17 Crowell, T. A. et al. Acute Retroviral Syndrome Is Associated With High Viral
8 Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue
9 Compartments. *Clin Infect Dis* 66, 1540-1549, doi:10.1093/cid/cix1063 (2018).
- 10

1 ACKNOWLEDGMENTS

2 The authors thank IAVI for supporting HIV-1 research studies and capacity building
3 initiatives in Kenya, Rwanda, and Zambia. They are also grateful to staff and volunteers from
4 IAVI's protocol B and C sites in Africa, without whom this work would not have been
5 possible. They also acknowledge the following people for their contributions, and support:
6 Malin Neptin (Department of Translational Medicine, Lund University, Sweden), Ashfaq Ali
7 (NBIS expert), Jakob Wilforss (Department of Immunotechnology, Lund University,
8 Sweden), Christofer Karlsson (Division of Infection Medicine, Department of Clinical
9 Sciences Lund, Faculty of Medicine, Lund University, Sweden), Hong Yan (Department of
10 Clinical Sciences, BioMS, Lund University, Sweden), and Johan Malmström (Division of
11 Infection Medicine, Department of Clinical Sciences Lund, Faculty of Medicine, Lund
12 University, Sweden).

13
14 This work was supported by the generous support of the American people through the United
15 States Agency for International Development (USAID). The contents are the responsibility of
16 the study authors and do not necessarily reflect the views of USAID, the National Institutes
17 of Health (NIH), or the US government. This work was also supported by funding from the
18 Swedish Research Council (grant numbers 2016-01417 and 2020-06262 to J.E) and the
19 Swedish Society for Medical Research (grant number SA-2016 to J.E). The authors are also
20 grateful for the support of the Sub-Saharan African Network for TB/HIV-1 Research
21 Excellence (SANTHE), a DELTAS Africa Initiative (grant number DEL-15-006 to A.S.H).
22 with support by the Wellcome Trust (grant number 107752/Z/15/Z), the UK Foreign,
23 Commonwealth & Development Office, through the Developing Excellence in Leadership,
24 Training and Science in Africa (DELTAS Africa) programme. J.N. was funded by the
25 Swedish Research Council (grant numbers 2016-01417 and 2020-06262) and the Medical

1 Faculty at Lund University. A. S. H. was supported by a training fellowship from the
2 Wellcome Trust (209294/Z/17/Z).

3

4 Disclaimer. This report was published with permission from the Kenya Medical Research
5 Institute (KEMRI).

6

7 **AUTHOR CONTRIBUTIONS**

8 J.E conceived the study. J.E, and A.S.H supervised the research. J.E, A.S.H, and J.N designed
9 the study. J.N and J.E. coordinated experiments and wrote the manuscript with inputs from all
10 authors. J.N, K.G and A.S.H curated the data. J.N, M.R, T.M, S.K performed the sample
11 preparation, LC-MS/MS analysis, and experiment optimisation. J.N, E.J, E.F, M.H, and F.A
12 wrote and optimised the original code used in the study, and performed the data analysis. J.N,
13 E.J, E.F, M.H, F.A, A.S.H, and J.E interpreted the results. All authors reviewed, and
14 approved the final version of the manuscript. The following authors managed the sites to
15 which participants were attended to and where samples were collected, provided clinical
16 expertise and/or provided clinical data for the participant samples: J.H, A.K, E.K, W.K,
17 M.A.P, P.K, S.A, E.H, T.N, J.G, S.R.J, and E.J.S.

18

1 **COMPETING INTERESTS**

2 The authors declare no competing interests.

3

4 **ADDITIONAL INFORMATION**

5 **Supplementary information** is available for this paper.

6 **Correspondence and requests for materials** should be addressed to J.E.

7 **Peer review information**

8 **Reprints and permissions information** is available at <http://www.nature.com/reprints>.

1 **Extended Data Table 1 | Characteristics of study participants diagnosed with**
 2 **Hyperacute HIV-1 infection.**

Characteristics	Total (N = 54)	Females (N = 20)	Males (N = 34)
Age in years			
Median age (IQR)	24 (22-27)	22 (21-24)	26 (22-31)
Below age 25 (%)	32 (59)	15 (75)	17 (50)
Above age 25 (%)	22 (41)	5 (25)	17 (50)
Country of collection (Site, %)			
Kenya (Kilifi)	32 (59)	3 (15)	29 (85)
Rwanda (Kigali)	4 (7)	2 (10)	2 (6)
Zambia (Lusaka)	3 (6)	0 (0)	3 (9)
South Africa (Durban)	15 (28)	15 (75)	0 (0)
HIV-1 subtype (%)			
A1	31 (57)	5 (25)	26 (76)
A2D	1 (2)	0 (0)	1 (3)
C	20 (37)	15 (75)	5 (15)
D	1 (2)	0 (0)	1 (3)
G	1 (2)	0 (0)	1 (3)
Risk group (%)			
DC	7 (13)	2 (10)	5 (15)
HET	19 (35)	18 (90)	1 (3)
MSM	28 (52)	0 (0)	28 (82)
Median time in days from EDI (IQR)			
Pre-infection (V0)	62 (28-106)	59 (41-92)	71 (22-113)
After-Infection – Fiebig stage I (V1)	10 (7-14)	7 (7-10)	9 (10-14)
After-Infection – Fiebig stage II (V2)	31 (28-37)	29 (28-31)	32 (29-39)

3

1 **Extended Data Table 2 | Differentially expressed proteins in pre-infection and hyper**
 2 **acute stages of HIV-1.**

Protein	Protein description	Biological process	Secretome location	Tissue specificity
V1-V0: Increased at V1				
VWF	Von Willebrand factor	Blood coagulation, Cell adhesion, Haemostasis	Secreted to blood	Plasma
FN1	Fibronectin 1	Acute phase, Angiogenesis, Cell adhesion, Cell shape	Secreted to blood	Liver
V2-V0: Increased at V2				
TTN	Titin	cardiac muscle cell development	Leakage	Cardiac and skeletal muscle
HINT2	Histidine triad nucleotide binding 2	Apoptosis, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis	Leakage	Liver, Pancreas
VWF	Von Willebrand factor	Blood coagulation, Cell adhesion, Haemostasis	Secreted to blood	Plasma
FN1	Fibronectin 1	Acute phase, Angiogenesis, Cell adhesion, Cell shape	Secreted to blood	Liver
PAPOLA	Poly(A) polymerase alpha	mRNA processing	Leakage	Ubiquitous
RAB10	RAB10, member RAS oncogene family	Transport	Leakage	Hippocampus, testis
FLNA	Filamin A	Cilium biogenesis/degradation, actin cytoskeleton reorganisation	Leakage	Ubiquitous
HLA-A	Major histocompatibility complex, class I, A	Adaptive immunity, Host-virus interaction, Innate immunity	Leakage	Ubiquitous
V2-V0: Decreased at V2				
LTF	Lactotransferrin	Immunity, Ion transport, Osteogenesis, Transcription regulation	Secreted to blood	Plasma, tears, saliva,
PRDX2	Peroxiredoxin 2	T-cell proliferation	Leakage	Ubiquitous
FGL1	Fibrinogen like 1	Adaptive immunity, regulation of T-cell activation	Secreted to blood	Liver
ATF6	Activating transcription factor 6	Transcription regulation, Unfolded response	Leakage	Ubiquitous
V2-V1: Increased at V1				
PI16	Peptidase inhibitor 16	cardiac muscle cell development	Secreted to blood	Prostate, urinary bladder, testis
V2-V1: Decreased at V1				
HNRNPA2B1	Heterogeneous nuclear ribonucleo A2/B1	Host-virus interaction, mRNA processing/splicing/ transport	Leakage	Ubiquitous
PRDX2	Peroxiredoxin 2	T-cell proliferation	Leakage	Ubiquitous
MANBA	Mannosidase beta	glyco catabolic process	Leakage	Ubiquitous
HPN	Hepsin	positive regulation by host of viral transcription	Leakage	Liver, kidney
GRN	Granulin precursor	astrocyte activation involved in immune response	Secreted to blood	Kidney,

3

1 Extended Data Table 3 | Proteins associated with acute retroviral syndrome.

Protein	Protein description	Biological process	Secretome location	Tissue specificity
V1-V0: Increased among those with ARS				
KRT9	Keratin 9	Epithelial cell differentiation	Leakage	Lymphoid tissue
V1-V0: Decreased among those with ARS				
SCGB1A1	Secretoglobin family 1A member 1	Inflammatory response, negative regulation of IFN-gamma/IL-13/IL-4 production	Secreted in other tissues	Club cells
ZYX	Zyxin	Inflammatory response, Cell adhesion, Host-virus interaction, response to IFN-gamma	Leakage	Ubiquitous
PPBP	Pro-platelet basic protein	Inflammatory response, Chemotaxis	Secreted to blood	Bone marrow, lymphoid tissue
FCGR3A	Fc fragment of IgG receptor IIIa	ADCC, regulation of immune response, epithelial cell differentiation	Secreted to blood	Plasma
GSN	Gelsolin	Cellular response to interferon-gamma, viral entry into host cell, Cilium biogenesis	Secreted to blood	Plasma
ICOSLG	Inducible T-cell costimulator ligand	Adaptive immunity, B-cell activation, Immunity	Membrane	Ubiquitous
V2-V0: Increased among those with ARS				
ACTA2	Actin alpha 2	Cell motility, structure	Leakage	Smooth muscle
GDI2	GDP dissociation inhibitor 2	Signal transduction, vesicle mediated transport	Leakage	Brain
GSTO1	Glutathione S-transferase omega 1	Positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion	Leakage	Ubiquitous
PSMA1	Proteasome 20S subunit alpha 1	Inflammatory response, proteasomal protein catabolic process	Leakage	Ubiquitous
TMOD3	Tropomodulin 3	actin filament organisation	Leakage	Ubiquitous
TUBB	Tubulin beta class I	Cytoskeleton-dependent intracellular transport	Leakage	Spleen, thymus, brain
V2-V0: Decreased among those with ARS				
C2	Complement C2	complement activation, innate immunity	Leakage	Liver
CTSS	Cathepsin S	adaptive immune response, antigen processing and presentation	Leakage	Lymphoid tissue, bone marrow
HRG	Histidine rich glycoprotein	Fibrinolysis, platelet activation, actin cytoskeleton organization	Secreted to blood	Plasma
ICOSLG	Inducible T-cell costimulator ligand	Adaptive immunity, B-cell activation, Immunity	Membrane	Ubiquitous
PTPRG	Protein tyrosine phosphatase receptor type G	Negative regulation of epithelial cell migration	Membrane	Ubiquitous

2

1 Extended Data Table 4 | Proteins associated with viral control.

Protein	Protein description	Biological process	Secretome location	Tissue specificity
V1-V0: Increased among viral controllers				
ARHGAP18	Rho GTPase activating protein 18	Regulation of actin cytoskeleton organization/ cell motility	Leakage	
HSPA5	Heat shock protein family A (Hsp70) member 5	Host-virus interaction	Leakage	
V1-V0: Decreased among viral controllers				
FCGR3A	Fc fragment of IgG receptor IIIa	ADCC, regulation of immune response, epithelial cell differentiation	Secreted to blood	Plasma
SAA4	Serum amyloid A4, constitutive	Acute phase	Secreted to blood	Liver, Plasma
V2-V0: Decreased among viral controllers				
GPI	Glucose-6-phosphate isomerase	Gluconeogenesis, glycolysis	Secreted to blood	
THBS1	Thrombospondin 1	Cell adhesion, unfolded protein response	Secreted to extracellular matrix	
PGD	Phosphogluconate dehydrogenase	Gluconate utilization, pentose shunt	Leakage	
ITIH4	Inter-alpha-trypsin inhibitor heavy chain 4	Acute phase	Secreted to blood	Liver
PSG1	Pregnancy specific beta-1-glycoprotein 1	Regulation of immune system process, signal transduction	Secreted in female reproductive system	
LBP	Lipopolysaccharide binding protein	Innate immunity, lipid transport, transport	Secreted to blood	Serum
ANXA1	Annexin A1	Adaptive immunity, inflammatory response, innate immunity	Secreted to blood	Liver, serum
V2-V1: Increased among viral controllers				
RT86	Keratin 86	Intermediate filament organization	Leakage	hair
PLXNB1	Plexin B1	Cell migration and adhesion	Leakage	Kidney, brain
CFHR4	Complement factor H related 4	Complement activation	Secreted to blood	Liver, Plasma
MMRN2	Multimerin 2	Angiogenesis	Secreted to extracellular matrix	Endothelium
CST3	Cystatin C	Defence response, proteolysis	Secreted to blood	Plasma, CSF
V2-V1: Decreased among viral controllers				
TPI1	Triosephosphate isomerase 1	Gluconeogenesis, glycolysis	Leakage	
THBS1	Thrombospondin 1	Cell adhesion, unfolded protein response	Secreted to extracellular matrix	
FLNA	Filamin A	Cilium biogenesis/degradation	Leakage	Ubiquitous
VCP	Valosin containing protein	Autophagy, DNA damage, DNA repair, transport, Ubl conjugation pathway	Leakage	
SH3BGR2	SH3 domain binding glutamate rich protein like 2		Leakage	Brain, placenta, liver, kidney
YWHAQ	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta		Leakage	Brain, heart, pancreas
PF4V1	Platelet factor 4 variant 1	Inflammatory response, platelet activation	Secreted to blood	
SRGN	Serglycin	Apoptosis, biomineralization	Secreted to blood	
S100A9	S100 calcium binding protein A9	Apoptosis, autophagy, chemotaxis, immunity, inflammatory response, innate immunity	Secreted to blood	Serum
ARPC4	Actin related protein 2/3 complex subunit 4	Actin filament polymerisation	Leakage	
PDLIM1	PDZ and LIM domain 1	Actin cytoskeleton organization, transcription	Leakage	Heart, skeletal muscle


1 Extended Data Table 5 | Proteins associated with disease progression.

Protein	Protein description	Biological process	Secretome location	Tissue specificity
V1-V0: Increase increases risk of progression /Increased among fast progressors				
HPN	Hepsin	Positive regulation by host of viral transcription	Membrane	Liver, kidney
PRKCB	Protein kinase C beta	Adaptive immunity, apoptosis, transcription regulation	Leakage	
APOC4	Apolipoprotein C4	Lipid transport, transport	Secreted to blood	Liver, plasma
PSMB6	Proteasome 20S subunit beta 6	Host-virus interaction	Leakage	
TXNDC5	Thioredoxin domain containing 5	Negative regulation of apoptotic process, protein folding	Intracellular and membrane	
CRHBP	Corticotropin releasing hormone binding protein	Inflammatory response	Secreted to blood	
V1-V0: Decrease increases risk of progression /Decreased among fast progressors				
GSTM2	Glutathione S-transferase mu 2	<i>Regulation of release of sequestered calcium ion</i>	<i>Leakage</i>	Muscle
V2-V0: Increase increases risk of progression /Increased among fast progressors				
ITGB3	Integrin subunit beta 3	Cell adhesion, host-virus interaction	Intracellular and membrane	
DDTL	D-dopachrome tautomerase like		Leakage	
UBB	Ubiquitin B	Protein ubiquitination	Leakage	
HSPA8	Heat shock protein family A (Hsp70) member 8	Host-virus interaction, mRNA processing, stress response, transcription	Leakage	Ubiquitous
V2-V0: Decrease increases risk of progression /Decreased among fast progressors				
CD84	CD84 molecule	Adaptive immunity, autophagy, cell adhesion, innate immunity	Leakage	Hematopoietic tissues
LTBP1	Latent transforming growth factor beta binding protein 1	Regulation of transforming growth factor beta activation	Secreted to extracellular matrix	Heart
V2-V1: Increase increases risk of progression /Increased among fast progressors				
CLU	Clusterin	Apoptosis, complement pathway, innate immunity	Secreted to blood	Plasma
C7	Complement C7	Complement alternate pathway, complement pathway, cytolysis, innate immunity	Secreted to blood	Plasma
C4BPA	Complement component 4 binding protein alpha	Complement pathway, innate immunity	Secreted to blood	Plasma
V2-V1: Decrease increases risk of progression /Decreased among fast progressors				
OAF	Out at first homolog		Secreted - unknown location	
PEPD	Peptidase D	Collagen degradation		
PPIF	Peptidylprolyl isomerase F	Apoptosis, necrosis	Leakage	
CD84	CD84 molecule	Adaptive immunity, autophagy, cell adhesion, immunity, innate immunity	Membrane	Hematopoietic tissues
CLIC1	Chloride intracellular channel 1	Ion transport, transport	Leakage	Heart, placenta, liver, kidney, pancreas
SLTM	SAFB like transcription modulator	Apoptosis, transcription, transcription regulation	Leakage	
FOXA1	Forkhead box A1	Transcription, transcription regulation	Leakage	
RTN4	Reticulon 4	Neurogenesis	Membrane	
ALOX12	Arachidonate 12-lipoxygenase, 12S type	Fatty acid metabolism, lipid metabolism	Leakage	Vascular smooth muscle cell

SERPIND1	Serpin family D member 1	Blood coagulation, chemotaxis, haemostasis	Secreted to blood	Liver, plasma
APOB	Apolipoprotein B	Cholesterol metabolism, lipid metabolism, lipid transport, steroid metabolism, sterol metabolism, transport	Secreted to blood	

1


1 Extended Data Fig. 1 | Protein pre-processing and quality control results.



2

3

1 **Extended Data Fig. 2 | Longitudinal plasma proteome based on mean protein**
 2 **intensities.**




3
 4 **b**

Cluster	Depleted	Neat	Enriched biological processes
1	79	19	cell adhesion extracellular structure organisation
2	215	31	Epithelial cell /kidney development complement activation cellular extravasation viral entry into host cell extracellular structure organisation
3	227	157	blood coagulation, fibrin clot formation regulation of glucose metabolic process intermediate filament cytoskeleton organisation
4	179	111	activation of immune response complement activation pyruvate metabolic process cytoskeleton organisation and protein transport
5	85	22	blood coagulation, fibrin clot formation acute-phase response activation of immune response
6	121	14	cytoskeleton organisation ubiquitin-dependent protein catabolic process regulation of apoptosis regulation of cellular biosynthetic process
7	37	19	acute-phase response activation of immune response
8	14	6	positive regulation of programmed cell death blood coagulation, fibrin clot formation negative regulation of hydrolase activity


5

1 Extended Data Fig. 3 | Protein expression different between cohorts.




2

3 Extended Data Fig. 4 | Acute HIV-1 associated tissue damage signatures.



4
5

1 Extended Data Fig. 5 | Classification of disease progression.



2
3

1 **Extended Data Table 1 | Characteristics of study participants diagnosed with**
2 **Hyperacute HIV-1 infection.** Abbreviations: HIV-1, human immunodeficiency virus type 1;
3 IQR, interquartile range. Risk group data: DC (serodiscordant couples), HET (heterosexual)
4 and MSM (men who have sex with men). Availability of matched pre-infection samples by
5 days from sampling to the estimated date of infection (EDI).

6
7 **Extended Data Table 2 | Differentially expressed proteins in pre-infection and hyper**
8 **acute stages of HIV-1.** The table presents a comprehensive description of differentially
9 expressed proteins that were observed during acute stages of HIV-1 infection. Significance
10 was determined using a stringent threshold of $p < 0.005$, $q < 0.005$, and $\log_2FC > 1$ through
11 Linear mixed models, while also ensuring differences were observed in both cohorts. The
12 Protein ID column displays the UniProtKB/Swiss-Prot entry name for each protein, while the
13 Protein description column provides the recommended full protein name from
14 UniProtKB/Swiss-Prot. The Biological process column captures either biological process
15 keywords from UniProtKB/TrEMBL or protein function information provided by the human
16 protein atlas. Secretome location provides information on the predicted location of the protein
17 based on signal peptide and transmembrane region prediction methods listed in HPA, or
18 alternatively, a description of the subcellular location of the mature protein (including
19 isoform locations if available) as described by UNIPROT. Tissue specificity was provided
20 through extracted information from UNIPROT and HPA on the expression of a gene at the
21 mRNA and protein level in cells or tissues of multicellular organisms.

22
23 **Extended Data Table 3 | Proteins associated with acute retroviral syndrome.** The table
24 presents a comprehensive description of statistically significant proteins at two weeks post
25 HIV-1 infection vs. pre-infection that are associated with ARS. Significance was determined

1 using a stringent threshold of $p < 0.005$, $q < 0.005$, and $\log_2FC > 1$ through linear mixed
2 modelling, while also ensuring differences were observed in both cohorts. The Protein ID
3 column displays the UniProtKB/Swiss-Prot entry name for each protein, while the Protein
4 description column provides the recommended full protein name from UniProtKB/Swiss-
5 Prot. The Biological process column captures either biological process keywords from
6 UniProtKB/TrEMBL or protein function information provided by the human protein atlas.
7 Secretome location provides information on the predicted location of the protein based on
8 signal peptide and transmembrane region prediction methods listed in HPA, or alternatively,
9 a description of the subcellular location of the mature protein (including isoform locations if
10 available) as described by UNIPROT. Tissue specificity is provided through extracted
11 information from UNIPROT and HPA on the expression of a gene at the mRNA and protein
12 level in cells or tissues of multicellular organisms.

13

14 **Extended Data Table 4 | Proteins associated with viral control.** The table presents a
15 comprehensive description of statistically significant/ proteins at two weeks post HIV-1
16 infection vs. pre-infection; one-month post HIV-1 infection vs. pre-infection; one-month vs
17 two-week post HIV-1 infection; that are associated with viral control. To determine
18 significance, a stringent threshold was set at $p < 0.005$, $q < 0.005$, and $\log_2FC > 1$, while also
19 ensuring differences were observed in both cohorts. The Protein ID column displays the
20 UniProtKB/Swiss-Prot entry name for each protein, while the Protein description column
21 provides the recommended full protein name from UniProtKB/Swiss-Prot. The Biological
22 process column captures either biological process keywords from UniProtKB/TrEMBL or
23 protein function information provided by the human protein atlas. Secretome location
24 provides information on the predicted location of the protein based on signal peptide and
25 transmembrane region prediction methods listed in HPA, or alternatively, a description of the

1 subcellular location of the mature protein (including isoform locations if available) as
2 described by UNIPROT. Tissue specificity is provided through extracted information from
3 UNIPROT and HPA on the expression of a gene at the mRNA and protein level in cells or
4 tissues of multicellular organisms.

5

6 **Extended Data Table 5 | Proteins associated with disease progression.** The table presents
7 a comprehensive description of statistically significant/ proteins at two weeks post HIV-1
8 infection vs. pre-infection; one-month post HIV-1 infection vs. pre-infection; one-month vs
9 two-week post HIV-1 infection; that are associated with disease progression. To determine
10 significance, a stringent threshold was at $p < 0.005$, $q < 0.005$, and $\log_2FC > 1$, while also
11 ensuring differences were observed in both cohorts. The Protein ID column displays the
12 UniProtKB/Swiss-Prot entry name for each protein, while the Protein description column
13 provides the recommended full protein name from UniProtKB/Swiss-Prot. The Biological
14 process column captures either biological process keywords from UniProtKB/TrEMBL or
15 protein function information provided by the human protein atlas. Secretome location
16 provides information on the predicted location of the protein based on signal peptide and
17 transmembrane region prediction methods listed in HPA, or alternatively, a description of the
18 subcellular location of the mature protein (including isoform locations if available) as
19 described by UNIPROT. Tissue specificity is provided through extracted information from
20 UNIPROT and HPA on the expression of a gene at the mRNA and protein level in cells or
21 tissues of multicellular organisms.

22

23 **Extended Data Fig. 1 | Protein pre-processing and quality control results. a,** Scatterplot
24 depicting the protein-wise relationship between median intensities and the proportion of
25 missing values for each sample preparation type in the left panel. Histograms illustrating the

1 frequencies of the proportion are presented alongside with density plots to the right. Protein-
2 wise investigation revealed inverse correlation indicating that proteins with lower median
3 signals generally exhibited more missing values. These trends align with the assumption of
4 missing values are not at random in DIA/SWATH data. **b**, Plot representing the proportion of
5 missing values across cohorts. The IAVI/East African cohort showed higher missingness
6 across all time points when compared to the South African cohort in both depleted and neat
7 plasma samples ($p < 0.005$; Welch Two Sample t-test).

8

9 **Extended Data Fig. 2 | Longitudinal plasma proteome based on mean protein**
10 **intensities. a**, Dendrogram illustrating hierarchical clustering with complete linkage for
11 longitudinal protein expression profiles during AHI. The dendrogram was based on the mean
12 protein expression profiles across all 54 patients i.e., 1336 protein combination values from
13 all three time points were analysed. Optimal clusters, indicative of distinct longitudinal
14 expression profiles, were identified using the elbow method, resulting in eight clusters. These
15 clusters were then color-coded and plotted, with the x-axis representing the visit number and
16 the y-axis reflecting the scaled mean log-intensity per protein. **b**, Summary of the number of
17 proteins in both depleted and neat; and enriched biological process terms per cluster.

18

19 **Extended Data Fig. 3 | Protein expression different between cohorts.** PCA plot illustrating
20 protein expression profiles in AHI samples longitudinally collected from 54 participants
21 across two cohorts. The x- and y- axes represent PCA 1 and 2, respectively, with the
22 explained percentage variance indicated on the axis labels in bracket. Cohorts are
23 distinguished by different symbols: “+” for the Durban/South African cohort and “o” for the
24 IAVI/East African cohort. To preprocess the protein expression data, missing values imputed
25 by replacing each with a randomly chosen value between one and the minimum of the protein

1 that has the missing value. The data was then log-2 transformed and normalised using the
2 Cyclic Loess method (normalizeCyclicLoess function in limma package v3.50.0) as
3 determined by NormalyzerDE.

4

5 **Extended Data Fig. 4 | Acute HIV-1 associated tissue damage signatures.** Dot plot
6 illustrating the results of gene set enrichment analysis for tissue damage signatures obtained
7 using a tissue damage library. Each dot represents a gene set and is positioned based on its
8 enrichment score and statistical significance. The size of the dot corresponds to the
9 significance of enrichment, with larger dots indicating higher significance. The color of the
10 dot represents the adjusted p-value associated with the protein set. Dots located below the
11 significance threshold ($p < 0.05$) indicate positive enrichment, signifying overrepresentation of
12 the gene set in the analysed data. The tissue damage signatures are displayed on the y-axis,
13 while the x-axis represents the Protein/GeneRatio.

14

15 **Extended Data Fig. 5 | Classification of disease progression. a,** Kaplan-Meier plot
16 displaying the estimated probability of survival against time to CD4+ T-cell counts < 500
17 cells/ μ l, starting from six weeks post estimated date of infection to ART start date. The
18 number of study participants at risk at regular time intervals is shown at the bottom of the
19 figure. **b,** A Kaplan-Meier plot displaying the differences in survival between females and
20 male study participants and a p-value of 0.08 from the Log rank test is indicative of no
21 significant difference in survival between males and females.